Overview

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
Phase:
PHASE1
Details
Lead Sponsor:
DualityBio Inc.
Collaborator:
GlaxoSmithKline